Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Sanofi”

A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥2 Years to <12 Years of Age With Uncontrolled Chronic Spontaneous Urticaria (CSU) (LIBERTY-CSU CUPIDKids)Completed
NCT05526521Phase 3Updated Nov 25, 2025
Sponsor: Sanofi
Chronic Spontaneous Urticaria
United States, Canada, Japan
Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast CancerTerminated
NCT03284957Phase 1, Phase 2Updated Nov 24, 2025
Sponsor: Sanofi
Breast Cancer
United States, Belgium, Canada, Czechia, France +5 more
Assessment of the Safety and Efficacy of Dupilumab in Children With Asthma (Liberty Asthma Excursion)Completed
NCT03560466Phase 3Updated Nov 21, 2025
Sponsor: Sanofi
Asthma
United States, Argentina, Australia, Brazil, Canada +13 more
Study to Evaluate the Safety and Immune Response of an Investigational Vaccine for the Prevention of RSV (Respiratory Syncytial Virus) and (hMPV) Human Metapneumovirus Infection in Participants Aged 60 to 75 YearsCompleted
NCT06583031Phase 1Updated Nov 20, 2025
Sponsor: Sanofi Pasteur, a Sanofi Company
RSV Infection · hMPV
Australia
Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial HypertrophyRecruiting
NCT06941870Phase 4Updated Nov 18, 2025
Sponsor: Sanofi
Factor VIII Deficiency
United States, Canada, Japan, Taiwan
Immunogenetic Profiling of Dupilumab for the Treatment of Atopic DermatitisCompleted
NCT03293030Phase 4Updated Nov 14, 2025
Sponsor: University of California, San Francisco
Atopic Dermatitis · Atopic Dermatitis Eczema · Eczema · Atopic Dermatitis and Related Conditions
United States
Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With GlioblastomaCompleted
NCT03746080Phase 2Updated Nov 14, 2025
Sponsor: Lawrence D Recht
Glioblastoma · Glioblastoma With Primitive Neuronal Component · Gliosarcoma · Malignant Glioma
United States
SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMMActive Not Recruiting
NCT05405166Phase 3Updated Nov 14, 2025
Sponsor: Sanofi
Plasma Cell Myeloma Recurrent
United States, Argentina, Australia, Brazil, Canada +16 more
A Study to Evaluate Efficacy and Safety of SAR441566 in Adults With Plaque PsoriasisCompleted
NCT06073119Phase 2Updated Nov 10, 2025
Sponsor: Sanofi
Psoriasis
United States, Argentina, Bulgaria, Canada, Chile +12 more
Efficacy of Dupilumab on Facilitated Food Introduction in Eosinophilic EsophagitisCompleted
NCT05247866Phase 4Updated Nov 10, 2025
Sponsor: Children's Hospital of Philadelphia
Eosinophilic Esophagitis
United States
Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in JapanActive Not Recruiting
NCT07216079Phase 3Updated Nov 6, 2025
Sponsor: Sanofi
Immune Thrombocytopenia
Japan
BEYFORTUS™ (Nirsevimab) Effectiveness Against Medically-Attended RSV Events in Infants (BEAR Study)Completed
NCT06325332N/AUpdated Nov 5, 2025
Sponsor: Sanofi Pasteur, a Sanofi Company
Respiratory Syncytial Virus
United States
A Real-world Long-term Safety and Immunogenicity Study of Olipudase Alfa Therapy in Pediatric Patients Less Than 2 Years of Age With Acid Sphingomyelinase Deficiency (ASMD)Recruiting
NCT06192576N/AUpdated Oct 31, 2025
Sponsor: Sanofi
Niemann-Pick Diseases · Acid Sphingomyelinase Deficiency
United States
Avalglucosidase Alfa French Post-trial Access for Participants With Pompe Disease (PTA Avalglucosidase)Active Not Recruiting
NCT05164055Phase 4Updated Oct 31, 2025
Sponsor: Genzyme, a Sanofi Company
Glycogen Storage Disease Type II
France
Immunogenicity Trial of 3 Influenza VaccinesCompleted
NCT05479370Phase 3Updated Oct 31, 2025
Sponsor: Tan Tock Seng Hospital
Influenza Vaccination
Singapore
Effect of Dronedarone on Atrial Fibrosis Progression and Atrial Fibrillation RecurrenceTerminated
NCT04704050Phase 4Updated Oct 30, 2025
Sponsor: Tulane University School of Medicine
Atrial Fibrillation · Atrial Fibrillation Recurrent
United States
Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLCTerminated
NCT04524689Phase 2Updated Oct 29, 2025
Sponsor: Sanofi
Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
United States, Brazil, Chile, Czechia, France +3 more
Proof-of-concept Study for SAR445088 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Completed
NCT04658472Phase 2Updated Oct 28, 2025
Sponsor: Bioverativ, a Sanofi company
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
United States, Canada, China, France, Germany +5 more
Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)Completed
NCT04394351Phase 3Updated Oct 27, 2025
Sponsor: Regeneron Pharmaceuticals
Eosinophilic Esophagitis (EoE)
United States, Canada
The Myelin Disorders Biorepository ProjectRecruiting
NCT03047369N/AUpdated Oct 23, 2025
Sponsor: Children's Hospital of Philadelphia
Leukodystrophy · White Matter Disease · Leukoencephalopathies · 4H Syndrome
United States
Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple SclerosisCompleted
NCT03996291Phase 2Updated Oct 23, 2025
Sponsor: Sanofi
Relapsing Multiple Sclerosis
United States, Canada, Czechia, Estonia, France +4 more
EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 PatientsCompleted
NCT04998604Phase 4Updated Oct 23, 2025
Sponsor: Sanofi
Chronic Rhinosinusitis With Nasal Polyps · Asthma
United States, Belgium, Canada, Czechia, Denmark +12 more
A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of FabrazymeCompleted
NCT06019728Phase 4Updated Oct 21, 2025
Sponsor: Sanofi
Fabry's Disease
United States
PRV-015 in Gluten-free Diet Non-responsive Celiac DiseaseCompleted
NCT04424927Phase 2Updated Oct 20, 2025
Sponsor: Provention Bio, a Sanofi Company
Celiac Disease
United States, Canada, Netherlands, Spain
Effect of Alemtuzumab on Microglial Activation Positron Emission Tomography (PET) in Multiple SclerosisWithdrawn
NCT03983252Phase 1, Phase 2Updated Oct 20, 2025
Sponsor: Brigham and Women's Hospital
Multiple Sclerosis
United States

Previous page Next page